Pegaptanib efficacious and non-toxic for ROP
Anti-VEGF therapy pegaptanib is efficacious and non-toxic for patients with retinopathy of prematurity (ROP), states a recent study.
Anti-VEGF therapy pegaptanib is efficacious and non-toxic for patients with retinopathy of prematurity (ROP), states a recent study.
Dr Helen A. Mintz-Hittner et al., Department of Ophthalmology and Visual Science, Robert Cizik Eye Centre, University of Texas, Health Science Centre at Houston Medical School, Houston, Texas, USA, conducted a prospective, randomized controlled clinical trial. Patients were split into those with ROP and a control group.
Using pegaptanib with laser therapy was efficacious in 91.2% of affected patients, compared to 69% of the control patients. Bevacizumab monotherapy was efficacious in 95.7% in affected patients, compared to 78.1% in controls.
Both anti-VEGF treatments were effective in treating ROP and there have been no toxicity incidences reported so far.
The European Journal of Ophthalmology. features the abstract in its latest issue.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
